Awareness of drug laboratory test interactions is important for prevention of unnecessary additional diagnostics: An example

Jasmijn A. van Balveren*, Lale Erdem-Eraslan, Wilhelmine P.H.G. Verboeket-van de Venne, Carine J.M. Doggen, Johannes Hofland, Wytze P. Oosterhuis, Yolanda B. de Rijke, Rein M.J. Hoedemakers, Ron Kusters

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)


Background: Elevated levels of Chromogranin A (CgA) may be indicative of a neuroendocrine tumour (NET), but increased levels are also observed after intake of proton pump inhibitors (PPIs). The incidence of diagnostic confusion because of this drug-laboratory test interaction (DLTI) was examined. Methods: Medical records of 238 patients with elevated CgA concentrations were obtained from three hospitals. The following data were extracted: PPI prescription at the time of CgA measurement, medical decision making based on elevated CgA concentrations, final diagnosis, comorbidity and other prescribed drugs. Results: From 238 patients with elevated CgA concentrations, 132 used PPIs. Of these patients, 57 patients did not have a NET. In 9 of these 57 patients (16%), diagnostic work up revealed no medical cause of an elevated CgA concentration. Somatostatin receptor imaging was ordered in 4 out of 9 cases, with no abnormalities observed. In 6 out of 9 cases, CgA measurement was repeated after PPI discontinuation resulting in normalisation of CgA concentrations. Conclusion: In this retrospective patient record study we observed that part of the elevated CgA concentrations in patients could be caused by the usage of PPIs causing unnecessary diagnostic work-up for the exclusion of a NET. These observations illustrate the need for better DLTI awareness.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalClinica Chimica Acta
Publication statusPublished - 1 May 2022

Bibliographical note

Funding Information: Not applicable. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Publisher Copyright: © 2022 Elsevier B.V.


Dive into the research topics of 'Awareness of drug laboratory test interactions is important for prevention of unnecessary additional diagnostics: An example'. Together they form a unique fingerprint.

Cite this